- Markets
- ToolsPortfoliosTrack performance, allocation, dividends, and risksStock screenerFilter, compare, and track stocksInsiders tradingSee how executives tradeHistogramSee ratios across industriesSaved screenersMy highlights
- Sign in
- Sign up for free
- 1
- Portfolios
- Tools
- Stock screener
- Cryptocurrency screener
- Insiders trading
- SEC filings
- Bubbles
- Histogram
- Markets
Sign inSign up for free
The estimated Net Worth of Wayne P. Rothbaum is at least $335 Million dollars as of 20 February 2024. Mr. Rothbaum owns over 5,000,000 units of Iovance Biotherapeutics Inc stock worth over $334,562,609 and over the last 5 years he sold IOVA stock worth over $0. In addition, he makes $0 as Independent Director at Iovance Biotherapeutics Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Already have an account? Sign in
or
Sign up with GoogleSign up with Facebook
Mr. Rothbaum IOVA stock SEC Form 4 insiders trading
Wayne has made over 5 trades of the Iovance Biotherapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 5,000,000 units of IOVA stock worth $45,750,000 on 20 February 2024.
The largest trade he's ever made was buying 10,000,000 units of Iovance Biotherapeutics Inc stock on 2 December 2022 worth over $65,000,000. On average, Wayne trades about 3,703,509 units every 317 days since 2018. As of 20 February 2024 he still owns at least 28,067,333 units of Iovance Biotherapeutics Inc stock.
You can see the complete history of Mr. Rothbaum stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Already have an account? Sign in
or
Sign up with GoogleSign up with Facebook
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
WayneRothbaum biography
Wayne P. Rothbaum serves as Independent Director of the Company. Mr. Rothbaum joined our Board of Directors on June 7, 2016. Mr. Rothbaum is currently the President of Quogue Capital LLC, a life sciences investment fund he founded in 2001. Beginning in 2012, Mr. Rothbaum served as the co-founder and largest investor of Acerta Pharma, B.V., a Dutch biotech focused on developing selective, covalent small molecules to treat cancer and inflammation. Acerta Pharma was sold to AstraZeneca in February 2016. From February 2013 until its sale in February 2016, Mr. Rothbaum served as the executive chairman of Acerta Pharma. From 1993 until 2001, Mr. Rothbaum led the biotechnology practice at the strategic consulting firm The Carson Group. Mr. Rothbaum graduated Phi Beta Kappa from Binghamton University in 1990 with a dual major in political science and psychology and received his master’s degree in international economics from the George Washington University.
How old is Wayne Rothbaum?
Wayne Rothbaum is 52, he's been the Independent Director of Iovance Biotherapeutics Inc since 2016. There are 8 older and 6 younger executives at Iovance Biotherapeutics Inc. The oldest executive at Iovance Biotherapeutics Inc is MerrillMcPeak, 84, who is the Independent Director.
What's Wayne Rothbaum's mailing address?
Wayne's mailing address filed with the SEC is 999 Skyway Rd #150, San Carlos, CA 94070, USA.
Insiders trading at Iovance Biotherapeutics Inc
Over the last 7 years, insiders at Iovance Biotherapeutics Inc have traded over $0 worth of Iovance Biotherapeutics Inc stock and bought 22,614,553 units worth $159,655,586. The most active insiders traders include Wayne P. Rothbaum, Merrill A Mcpeak, and Timothy E Morris.On average, Iovance Biotherapeutics Inc executives and independent directors trade stock every 44 days with the average trade being worth of $6,281,765. The most recent stock trade was executed by Finckenstein Friedrich Graf on 4 March 2024, trading 15,623 units of IOVA stock currently worth $187,320.
What does Iovance Biotherapeutics Inc do?
iovance biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (til). this approach, also known as adoptive t-cell therapy, was initially developed by dr. steven a. rosenberg at the national cancer institute (nci). in phase 2 clinical trials conducted at the nci, 56% and 24% of patients treated with this technology were reported by nci to have achieved objective and complete response criteria, respectively. our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. in addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our til therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. as we continue advancing our current clinical programs through the introduction of manufacturing and logistical
What does Iovance Biotherapeutics Inc's logo look like?
Complete history of Mr. Rothbaum stock trades at Iovance Biotherapeutics Inc
| Date | # Company | Insider | Trans. Transaction | Shares | Price per share | Total value | Shares after | Source |
|---|---|---|---|---|---|---|---|---|
| 20 Feb 2024 | IOVAIovance Biotherapeutics Inc | Wayne P. Rothbaum Director | Buy | 5,000,000 | $9.15 | $45,750,000 20 Feb 2024 | 28,067,333 | ↗ |
| 15 Sep 2023 | IOVAIovance Biotherapeutics Inc | Wayne P. Rothbaum Director | Buy | 5,000,000 | $5.30 | $26,500,000 15 Sep 2023 | 23,067,333 | ↗ |
| 2 Dec 2022 | IOVAIovance Biotherapeutics Inc | Wayne P. Rothbaum Director | Buy | 10,000,000 | $6.50 | $65,000,000 2 Dec 2022 | 18,067,333 | ↗ |
| 31 May 2022 | IOVAIovance Biotherapeutics Inc | Wayne P. Rothbaum Director | Buy | 1,000,000 | $6.60 | $6,600,000 31 May 2022 | 8,067,333 | ↗ |
| 4 Dec 2018 | IOVAIovance Biotherapeutics Inc | Wayne P. Rothbaum Director | Buy | 1,221,053 | $10.20 | $12,454,741 4 Dec 2018 | 7,067,333 | ↗ |
Iovance Biotherapeutics Inc executives and stock owners
Iovance Biotherapeutics Inc executives and other stock owners filed with the SEC include:
- MariaFardis,
President, Chief Executive Officer and Director - FriedrichGraf Finckenstein,
Chief Medical Officer - FrederickVogt,
General Counsel, Corporate Secretary - IainDukes,
Chairman of the Board - MichaelWeiser,
Independent Director - Jean-Marc Bellemin M.B.A.,
Chief Financial Officer & Principal Accounting Officer - Dr. Friedrich Graf Finckenstein M.D.,
Chief Medical Officer - Dr. Frederick G. Vogt Esq., J.D., Ph.D.,
Interim Pres, CEO, Gen. Counsel & Corp. Sec. - MerrillMcPeak,
Independent Director - RyanMaynard,
Independent Director - AthenaCountouriotis,
Director - MichaelSwartzburg,
Interim Principal Financial Officer and Principal Accounting Officer - SaraPellegrino,
IR Contact Officer - WayneRothbaum,
Independent Director - Dr. Elma S. Hawkins,
Advisor to the Board - Madan Jagasia,
Sr. VP of Medical Affairs - James Ziegler,
Sr. VP of Commercial - Howard B. Johnson,
Sr. VP of Corp. Devel., Alliance Management & Program Management - Dr. Igor P. Bilinsky,
Chief Operating Officer - Timothy E Morris,
Chief Financial Officer - Jean Marc Bellemin,
Chief Financial Officer - Igor Bilinsky,
Chief Operating Officer - Wendy L Yarno,
Director - Wendy L Dixon,
Director
"A killer stock screener."
— Berry M., Switzerland
Give wallmine a try – it's free.
